FTSE 100 news / Companies and sectors / Pharma and healthcare / 3 October 2026
Pharma and healthcare: sector news on Saturday 3 October 2026
Average tone +1.4 (neutral) across 3 companies with relevant coverage, from 36 stories.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| AstraZeneca | +6.0 | 34 | Coverage was dominated by AstraZeneca's $2bn investment in Summit Therapeutics and a clinical collaboration with Daiichi Sankyo to test Datroway with ivonescimab, which was framed positively for its oncology pipeline. |
| GSK | −3.0 | 1 | Coverage was thin, with the only relevant story saying a voting rights update pressured GSK's share price near a resistance level. |
| Smith & Nephew | +1.3 | 1 | Coverage was limited to a single dividend analysis article on Smith & Nephew. |
| Convatec | – | 0 | |
| Haleon | – | 0 |
Strongest stories in the sector
- +8.3 Summit Deal Could Help Futureproof AstraZeneca’s Datroway
Deal seen as helping extend Datroway's future - +8.3 AstraZeneca invests $2bn in Summit Therapeutics, deepening oncology ADC-bispecific ties
$2bn investment deepens oncology ADC-bispecific position - +7.5 Summit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial Collaboration
AstraZeneca's $2bn partnership with Summit announced - +7.5 AstraZeneca, Daiichi Sankyo Team With Summit on Triple-Negative Breast Cancer Trial
Trial collaboration in triple-negative breast cancer - +7.5 AstraZeneca PLC, Daiichi Sankyo And Summit Therapeutics Inc. Announce Clinical Collaboration To Evaluate Datroway In Combination With Ivonescimab Across Multiple Tumour Types
Clinical collaboration to test Datroway combination - +7.0 AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact
Deepened Summit ties for ADC-bispecific combo testing - +7.0 AstraZeneca, Daiichi Sankyo, and Summit to Combine Datroway, Ivonescimab
Datroway and ivonescimab combination collaboration - +7.0 AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership
Expands cancer push through Summit partnership - +7.0 AstraZeneca et Daiichi Sankyo s'associent à Summit pour tester une association de médicaments anticancéreux
Partnership to test cancer drug combination - +7.0 AstraZeneca, Daiichi team with Summit to pair Datroway with ivonescimab in Phase III TNBC push
Phase III TNBC push pairing Datroway with ivonescimab - +6.7 AstraZeneca and Daiichi Sankyo Team With Summit on Datroway Combination Trials
Datroway combination trials with Summit and Daiichi - +6.7 EU revokes Hansoh's Aumseqa nod after AstraZeneca challenge
AstraZeneca's challenge succeeded in EU revocation
Pharma and healthcare: every day · FTSE 100 overview for the day